The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 \[NCT01421524\], CC-122-ST-002 \[NCT02509039\], CC-122-DBCL-001 \[NCT02031419\], and CC-122-NHL-001 \[NCT02417285\]), receiving clinical benefit from the treatment and to monitor the safety and tolerability of CC-122.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
12
Specified dose on specified days
Specified dose on specified days
Local Institution - 100
New York, New York, United States
Local Institution - 101
Nashville, Tennessee, United States
Local Institution - 102
Madison, Wisconsin, United States
Local Institution - 300
Bordeaux, France
Number of participants with serious adverse events (SAEs) for participants who received at least 1 dose of CC-122
Time frame: Up to approximately 3 years
Number of deaths for participants who received at least 1 dose of CC-122
Time frame: Up to approximately 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Local Institution - 301
Marseille, France
Local Institution - 500
Koto-ku, Tokyo, Japan
Local Institution - 400
Amsterdam, Netherlands